The Counterfeit Detection Gap: How Pharma Brand Protection Quietly Became a Liability Question

OVERVIEW

In December 2023, the FDA seized counterfeit Ozempic (semaglutide) from the legitimate U.S. supply chain. It happened again in April 2025, and again in December 2025. In the most recent case, the counterfeit pens carried authentic lot numbers.

The only difference detectable by visual inspection was the misplacement of expiration text on the label—a detail most brand protection teams, supply chain integrity inspectors, pharmacists, and distributors would never catch. That is not a miss on visual QC. It is what happens when cloned credentials ride on packaging that was rebuilt, not serialized uniquely.

This white paper explains why that gap now sits with brand, legal, and executive teams, not only operations, and what the highest-performing brand protection teams need to do differently to protect their brand, revenues, and patients. Because today, the emerging challenge is catching the counterfeit that has the right lot number.

Introduction

Pharmaceutical counterfeiting has always been a threat facing brands around the world. But in recent years, the character of this threat has changed. The challenge is no longer only crude fakes in unregulated markets. It is identifying highly sophisticated counterfeits that enter through licensed channels, carry genuine lot numbers, and pass the identifiers and controls that most manufacturers already use.

For brand protection teams, this results in two consequences:

• First, serialization and overt features leave a detection gap. Counterfeiters can copy a real lot number onto new (i.e., fake) packaging they created themselves. The scans of these fakes return as authentic because the lot data is authentic. These packs do not carry a covert mark, for example, to help detect fakes, so today’s pharma controls might not see the difference. That gap has to be closed in the field, at scale.
• Second, brand protection is no longer just a supply chain function. When a counterfeit reaches a patient, it becomes a legal, financial, and reputational event that the brand has to manage.

When a patient is harmed by a product bearing your brand’s name, even if you didn’t directly manufacture it, your company already absorbs the initial scrutiny, recall costs, and reputational damage. It is your company’s name on the package.

This white paper examines the changing nature of counterfeit threats, the risks and decisions facing brand, executive, and legal teams, and the case for adding a new, covert digital authentication layer to packaging that can close the detection gap. What that layer adds is a field check inspectors can run when the printed lot number is no longer enough.